Identification of a gene expression profile that discriminates indirect-acting genotoxins from direct-acting

Ting Hu1, David P Gibson, Gregory J Carr

  • 1The Procter and Gamble Company, Miami Valley Laboratories, P.O. Box 538707 09, Cincinnati, OH 45253-8707, USA.

Mutation Research
|May 4, 2004
PubMed

Insights

Identifying genotoxic mechanisms is crucial for drug safety. This study uses gene expression analysis to differentiate direct-acting genotoxins from indirect-acting ones, offering a more efficient risk assessment method.

Area of Science:

  • Toxicology
  • Molecular Biology
  • Genetics

Background:

  • In vitro genotoxicity assays are standard for new drug safety evaluations.
  • Positive results necessitate costly, time-consuming, animal-utilizing follow-up studies.
  • Efficient methods to identify genotoxin mechanisms, particularly indirect ones, are needed for improved risk assessment.

Purpose of the Study:

  • To evaluate gene expression tools for discriminating between direct-acting and indirect-acting genotoxins.
  • To identify gene expression patterns that serve as a fingerprint for genotoxin classification.
  • To improve the efficiency and reduce animal use in genotoxicity risk assessment.

Main Methods:

  • Gene expression changes and micronuclei formation were analyzed in L5178Y mouse lymphoma cells.
  • Cells were treated with six model genotoxins: direct-acting (MMC, CIS, MMS) and indirect-acting (HU, TXL, ETOP).
  • Microarray analysis (Affymetrix) was performed on RNA samples at 4 and 24 hours post-treatment.

Main Results:

  • Differentially regulated genes were identified at both 4 and 24-hour time points.
  • These gene expression changes showed discriminating power between direct and indirect genotoxins.
  • The findings suggest a potential gene expression fingerprint for classifying genotoxins based on their mechanism of action.

Conclusions:

  • Gene expression profiling can effectively distinguish between direct and indirect genotoxins.
  • This approach offers a more efficient alternative to traditional follow-up studies.
  • The identified gene expression patterns may serve as a valuable tool for genotoxin classification and risk assessment.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...